IGC Pharma, Inc.

Climate Impact & Sustainability Data (2024)

Concentrated sales and suppliers representing some risk
Global operations exposed to currency fluctuations, political instability, and regulatory changes
Complexity and rapid development of AI initiatives
Perception as a 'cannabis company' hindering fundraising
Inexperience in conducting pre-clinical and clinical trials
Regulatory approval processes for IGC-AD1 and other product candidates
Limited success in Alzheimer's disease drug development
Potential for serious adverse events or undesirable side effects
Uncertainty regarding market acceptance of products
Lack of visibility regarding future demand for products
Business interruptions
Climate change concerns
Reliance on management team
Variability of quarterly revenue and profitability
Potential risks associated with the disposal of non-core assets
Risk of write-downs on inventory and other assets
Potential for unintentional accounting errors
Complex and changing laws and regulations related to climate change and ESG initiatives
Concentrated insider ownership of common stock

Established an internal CRO with proprietary software to optimize trial costs
Implementing tighter cybersecurity measures
Actively managing the disposal process of non-core assets to mitigate risks and maximize shareholder value
Regularly reviews long-lived assets for impairment
Strive to improve ESG performance and meet voluntary goals
Implementing a comprehensive cybersecurity program

Extreme weather events that could damage facilities and equipment, injure employees, disrupt operations, and negatively affect the ability to service clients

Disorderly global transition away from fossil fuels, customer preference for low-carbon products, stakeholder pressure to decarbonize, and new legal or regulatory requirements